OBLN - オバロン・セラピュ―ティクス (Obalon Therapeutics Inc.)

OBLNのニュース

   Obalon Therapeutics Wall street estimates Earnings report Stock market Insights & financial analysis  2021/03/11 00:47:00 Stock Market Daily
Obalon Therapeutics announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   31 Stocks Moving in Wednesday's Pre-Market Session  2021/03/10 12:19:45 Benzinga
Gainers MediciNova, Inc. (NASDAQ: MNOV ) shares rose 79.6% to $10.20 in pre-market trading after the biopharmaceutical company announced a partnership with the Biomedical Advanced Research and Development Authority (BARDA) to repurpose MN-166 (ibudilast) as a potential medical countermeasure against lung damage induced by chlorine gas. Exela Technologies, Inc. (NASDAQ: XELA ) rose 72.9% to $7.97 in pre-market trading. Exela Technologies shares jumped 179% on Tuesday after the company said it won a 10-year, $90-million contract delivering data transformation solutions for a major US insurer. Obalon Therapeutics, Inc. (NASDAQ: OBLN ) rose 50% to $5.31 in pre-market trading after climbing 18% on Tuesday. Atossa Therapeutics, Inc. (NASDAQ: ATOS ) shares rose 40.3% to $3.48 in pre-market trading after gaining over 16% on Tuesday. Atossa Therapeutics, last month, announced final results from its Phase 1 study evaluating AT-301 administered by nasal spray. AT-301 is being developed for at-home use for patients recently diagnosed with COVID-19..
   New Comprehensive Report on Obesity Intervention Devices Market 2020-2027| EnteroMedics, Apollo Endosurgery, Cousin Biotech, Aspire Bariatrics, Obalon Therapeutics  2020/11/23 12:44:49 OpenPR
HealthCare Intelligence Markets unravels its new study titled Obesity Intervention Devices Market. Effective exploratory techniques such as qualitative and quantitative analysis have been used to discover accurate data. For an effective business outlook, it studies North America, Latin America, Asia-Pacific,
   The Daily Biotech Pulse: Sanofi, Regeneron Finalize Praluent Restructuring, Natus Pre-Announces Q1 Shortfall, Alcon To Delay Dividend Initiation  2020/04/07 11:55:37 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs April 6.) Forty Seven Inc (NASDAQ: FTSV ) Masimo Corporation (NASDAQ: MASI ) Seattle Genetics, Inc. (NASDAQ: SGEN ) Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) Down In The Dumps (Biotech stocks that hit 52-week lows April 6) BIOLASE Inc (NASDAQ: BIOL ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) ENDRA Life Sciences Inc (NASDAQ: NDRA ) Global Cord Blood Corp (NYSE: CO ) ImmuCell Corporation (NASDAQ: ICCC ) IMMURON LTD/S ADR (NASDAQ: IMRN ) Menlo Therapeutics Inc (NASDAQ: MNLO ) (flunked two late-stage studies that evaluated oral serlopitant for treating pruritus associated with prurigo nodularis) Merus NV (NASDAQ: MRUS ) Millendo Therapeutics Inc (NASDAQ: MLND ) (said it is discontinuing development of livoletide as a potential treatment for Prader-Willi syndrome following failed Phase 2b study) Obalon Therapeutics Inc (NASDAQ: OBLN ) Quest Diagnostics Inc (NYSE: DGX ) (said it has performed 550,000 COVID-19 tests) Second Sight Medical Products Inc (NASDAQ: EYES ) Stocks In Focus Sanofi, Regeneron Finalize Previously Announced Praluent Restructuring Sanofi SA (NASDAQ: SNY ) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) announced they have finalized the planned restructuring related to cholesterol drug Praluent.
   Obalon +8.6% on new stock purchase agreement  2020/02/07 23:27:06 Seeking Alpha
Obalon Therapeutics (NASDAQ:OBLN) is up 8.6% postmarket after entering into a new stock purchase agreement and registration rights agreement with Lincoln P
   Obalon Therapeutics Wall street estimates Earnings report Stock market Insights & financial analysis  2021/03/11 00:47:00 Stock Market Daily
Obalon Therapeutics announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   31 Stocks Moving in Wednesday's Pre-Market Session  2021/03/10 12:19:45 Benzinga
Gainers MediciNova, Inc. (NASDAQ: MNOV ) shares rose 79.6% to $10.20 in pre-market trading after the biopharmaceutical company announced a partnership with the Biomedical Advanced Research and Development Authority (BARDA) to repurpose MN-166 (ibudilast) as a potential medical countermeasure against lung damage induced by chlorine gas. Exela Technologies, Inc. (NASDAQ: XELA ) rose 72.9% to $7.97 in pre-market trading. Exela Technologies shares jumped 179% on Tuesday after the company said it won a 10-year, $90-million contract delivering data transformation solutions for a major US insurer. Obalon Therapeutics, Inc. (NASDAQ: OBLN ) rose 50% to $5.31 in pre-market trading after climbing 18% on Tuesday. Atossa Therapeutics, Inc. (NASDAQ: ATOS ) shares rose 40.3% to $3.48 in pre-market trading after gaining over 16% on Tuesday. Atossa Therapeutics, last month, announced final results from its Phase 1 study evaluating AT-301 administered by nasal spray. AT-301 is being developed for at-home use for patients recently diagnosed with COVID-19..
   New Comprehensive Report on Obesity Intervention Devices Market 2020-2027| EnteroMedics, Apollo Endosurgery, Cousin Biotech, Aspire Bariatrics, Obalon Therapeutics  2020/11/23 12:44:49 OpenPR
HealthCare Intelligence Markets unravels its new study titled Obesity Intervention Devices Market. Effective exploratory techniques such as qualitative and quantitative analysis have been used to discover accurate data. For an effective business outlook, it studies North America, Latin America, Asia-Pacific,
   The Daily Biotech Pulse: Sanofi, Regeneron Finalize Praluent Restructuring, Natus Pre-Announces Q1 Shortfall, Alcon To Delay Dividend Initiation  2020/04/07 11:55:37 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs April 6.) Forty Seven Inc (NASDAQ: FTSV ) Masimo Corporation (NASDAQ: MASI ) Seattle Genetics, Inc. (NASDAQ: SGEN ) Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) Down In The Dumps (Biotech stocks that hit 52-week lows April 6) BIOLASE Inc (NASDAQ: BIOL ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) ENDRA Life Sciences Inc (NASDAQ: NDRA ) Global Cord Blood Corp (NYSE: CO ) ImmuCell Corporation (NASDAQ: ICCC ) IMMURON LTD/S ADR (NASDAQ: IMRN ) Menlo Therapeutics Inc (NASDAQ: MNLO ) (flunked two late-stage studies that evaluated oral serlopitant for treating pruritus associated with prurigo nodularis) Merus NV (NASDAQ: MRUS ) Millendo Therapeutics Inc (NASDAQ: MLND ) (said it is discontinuing development of livoletide as a potential treatment for Prader-Willi syndrome following failed Phase 2b study) Obalon Therapeutics Inc (NASDAQ: OBLN ) Quest Diagnostics Inc (NYSE: DGX ) (said it has performed 550,000 COVID-19 tests) Second Sight Medical Products Inc (NASDAQ: EYES ) Stocks In Focus Sanofi, Regeneron Finalize Previously Announced Praluent Restructuring Sanofi SA (NASDAQ: SNY ) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) announced they have finalized the planned restructuring related to cholesterol drug Praluent.
   Obalon +8.6% on new stock purchase agreement  2020/02/07 23:27:06 Seeking Alpha
Obalon Therapeutics (NASDAQ:OBLN) is up 8.6% postmarket after entering into a new stock purchase agreement and registration rights agreement with Lincoln P
   New Comprehensive Report on Obesity Intervention Devices Market 2020-2027| EnteroMedics, Apollo Endosurgery, Cousin Biotech, Aspire Bariatrics, Obalon Therapeutics  2020/11/23 12:44:49 OpenPR
HealthCare Intelligence Markets unravels its new study titled Obesity Intervention Devices Market. Effective exploratory techniques such as qualitative and quantitative analysis have been used to discover accurate data. For an effective business outlook, it studies North America, Latin America, Asia-Pacific,
   The Daily Biotech Pulse: Sanofi, Regeneron Finalize Praluent Restructuring, Natus Pre-Announces Q1 Shortfall, Alcon To Delay Dividend Initiation  2020/04/07 11:55:37 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs April 6.) Forty Seven Inc (NASDAQ: FTSV ) Masimo Corporation (NASDAQ: MASI ) Seattle Genetics, Inc. (NASDAQ: SGEN ) Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) Down In The Dumps (Biotech stocks that hit 52-week lows April 6) BIOLASE Inc (NASDAQ: BIOL ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) ENDRA Life Sciences Inc (NASDAQ: NDRA ) Global Cord Blood Corp (NYSE: CO ) ImmuCell Corporation (NASDAQ: ICCC ) IMMURON LTD/S ADR (NASDAQ: IMRN ) Menlo Therapeutics Inc (NASDAQ: MNLO ) (flunked two late-stage studies that evaluated oral serlopitant for treating pruritus associated with prurigo nodularis) Merus NV (NASDAQ: MRUS ) Millendo Therapeutics Inc (NASDAQ: MLND ) (said it is discontinuing development of livoletide as a potential treatment for Prader-Willi syndrome following failed Phase 2b study) Obalon Therapeutics Inc (NASDAQ: OBLN ) Quest Diagnostics Inc (NYSE: DGX ) (said it has performed 550,000 COVID-19 tests) Second Sight Medical Products Inc (NASDAQ: EYES ) Stocks In Focus Sanofi, Regeneron Finalize Previously Announced Praluent Restructuring Sanofi SA (NASDAQ: SNY ) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) announced they have finalized the planned restructuring related to cholesterol drug Praluent.
   Obalon +8.6% on new stock purchase agreement  2020/02/07 23:27:06 Seeking Alpha
Obalon Therapeutics (NASDAQ:OBLN) is up 8.6% postmarket after entering into a new stock purchase agreement and registration rights agreement with Lincoln P
   Is OBALON THERPTCS (OBLN) Stock Outpacing Its Medical Peers This Year?  2020/01/24 16:30:10 Zacks Investment Research
Is (OBLN) Outperforming Other Medical Stocks This Year?
   Obalon Therapeutics Inc (NASDAQ:OBLN) CEO Buys $107,900.00 in Stock  2019/11/17 12:38:32 Modern Readers
Obalon Therapeutics Inc (NASDAQ:OBLN) CEO William J. Plovanic acquired 65,000 shares of the stock in a transaction dated Tuesday, November 12th. The shares were purchased at an average cost of $1.66 per share, with a total value of $107,900.00. Following the completion of the purchase, the chief executive officer now owns 106,806 shares of the […]

calendar